DelveInsight’s Chronic Spontaneous Urticaria pipeline report provides comprehensive coverage of the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
Key Takeaways from the Chronic Spontaneous Urticaria Pipeline Report
There are currently 20+ drugs in the Chronic Spontaneous Urticaria pipeline.
The Chronic Spontaneous Urticaria pipeline consists of therapies in different clinical phase stages, including Dupilumab, Ligelizumab, AK002, Tezepelumab, UB-221, CDX-0159, and others.
Leading companies actively working to improve the Chronic Spontaneous Urticaria treatment landscape are Regeneron, Novartis, Allakos, Amgen, United BioPharma, Celldex Therapeutics, and others.
Novartis announced in January 2021 that the U.S. Food and Drug Administration (FDA) had granted Ligelizumab (QGE031) Breakthrough Therapy designation for Chronic Spontaneous Urticaria (CSU) treatment.
Key Chronic Spontaneous Urticaria pipeline therapies in the early stage of development include UB-221 (United BioPharma), CDX-0159 (Celldex Therapeutics), along with others.
Get a detailed analysis of the pipeline landscape @ Chronic Spontaneous Urticaria Pipeline Analysis
Chronic Spontaneous Urticaria: Overview
Chronic Spontaneous Urticaria (CSU) is defined as hives that last at least 6 weeks and occur on the majority of days of the week. CSU is caused by the pathogenic activation of mast cells and basophils, which results in the release of proinflammatory mediators that contribute to the development of urticaria.
Chronic Spontaneous Urticaria Symptoms
Chronic Spontaneous Urticaria symptoms include:
Hives or wheals are raised or swollen welts on the skin that appear and disappear over the course of 6 weeks.
Itching that can be severe at times
Lips, eyelids, or throat swelling (angioedema)
Chronic Spontaneous Urticaria Treatment
The primary goal of Chronic Spontaneous Urticaria treatment is to eliminate symptoms such as pruritus, wheals, and angioedema. H1 antihistamines act as inverse agonists, combining with and stabilising the H1 receptor’s inactive conformation. Omalizumab, an IgG anti-IgE injectable antibody, was approved in 2014 to treat antihistamine-refractory CSU in people aged 12 and up. A plethora of other potential CSU therapeutics are currently being researched.
Chronic Spontaneous Urticaria Pipeline Analysis: Drug Profiles
Ligelizumab: Novartis
Product Description
Ligelizumab (QGE031) is a monoclonal anti-immunoglobulin E (IgE) antibody of the next generation. Ligelizumab is thought to work by inhibiting the IgE/FcRI pathway, which is a significant driver of the inflammatory process in CSU6.
Phase III
NCT04210843: Novartis launched a multi-centre, double-blind, open-label extension study in April 2020 to assess the efficacy and safety of ligelizumab as retreatment, self-administered therapy, and monotherapy in patients with chronic spontaneous urticaria who completed studies CQGE031C2302, CQGE031C2303, CQGE031C2202, or CQGE031C1301. The goal of this extension study is to determine ligelizumab’s efficacy and safety.
Chronic Spontaneous Urticaria Pipeline Therapies and Key Companies
Dupilumab: Regeneron
AK002: Allakos
Tezepelumab: Amgen
UB-221: United BioPharma
CDX-0159: Celldex Therapeutics
Find out the emerging therapies and companies @ Chronic Spontaneous Urticaria Clinical Trials
Chronic Spontaneous Urticaria Therapeutics Assessment
By Product Type
Monotherapy
Combination Therapy
By Stage
Discovery
Pre-Clinical
Phase I
Phase II
Pre-registration
By Route of Administration
Inhalation
Intravenous
Oral
Subcutaneous
By Molecule Type
Small Molecule
Stem Cell Therapy
Gene Therapy
Targets
Immune System
Multiple Kinase
By Mechanism of Action
Protease Inhibitors
Immunomodulatory
Scope of the Report
Coverage: Global
Chronic Spontaneous Urticaria Key Players: Regeneron, Novartis, Allakos, Amgen, United BioPharma, Celldex Therapeutics, among others
Chronic Spontaneous Urticaria Pipeline Therapies: Dupilumab, Ligelizumab, AK002, Tezepelumab, UB-221, CDX-0159, and others
Table of Contents
1.
Introduction
2.
Executive Summary
3.
4.
Chronic Spontaneous Urticaria- Analytical Perspective In-depth Commercial Assessment
5.
Chronic Spontaneous Urticaria Pipeline Therapeutics
6.
Chronic Spontaneous Urticaria Late Stage Products (Phase III)
7.
Chronic Spontaneous Urticaria Mid Stage Products (Phase II)
8.
Chronic Spontaneous Urticaria Early Stage Products (Phase I)
9.
Chronic Spontaneous Urticaria Therapeutic Assessment
10.
Chronic Spontaneous Urticaria Inactive Products
11.
Company-University Collaborations (Licensing/Partnering) Analysis
12.
Chronic Spontaneous Urticaria Key Companies
13.
Chronic Spontaneous Urticaria Key Products
14.
Chronic Spontaneous Urticaria- Unmet Needs
15.
Chronic Spontaneous Urticaria- Market Drivers and Barriers
16.
Chronic Spontaneous Urticaria- Future Perspectives and Conclusion
17.
Chronic Spontaneous Urticaria Analyst Views
18.
Appendix
19.
About DelveInsight
Get in touch with our business executive for Healthcare Due Diligence Services
Key questions answered in the Chronic Spontaneous Urticaria Pipeline Report
What treatments are available for Chronic Spontaneous Urticaria?
How many pharmaceutical companies are working on Chronic Spontaneous Urticaria treatments?
Which of these firms’ pharmaceuticals is the most widely used?
How many does Each company manufacture chronic Spontaneous Urticaria medications?
How many drugs for Chronic Spontaneous Urticaria are in the early, mid, or late stages of development?
How many of the currently being developed therapies can be used alone or in combination with other treatments?
What are the critical collaborations, mergers and acquisitions, and licencing practises in Chronic Spontaneous Urticaria?
Related Reports
Chronic Idiopathic Urticaria Pipeline Insight
Get a comprehensive analysis of Chronic Idiopathic Urticaria pipeline therapies and key companies, including Novartis, Regeneron, Amgen, AstraZeneca, United BioPharma, Celltrion, Celldex Therapeutics, among others.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/